Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $111.78.
A number of brokerages have weighed in on VKTX. Maxim Group restated a “buy” rating and issued a $120.00 target price on shares of Viking Therapeutics in a research note on Tuesday, June 4th. Truist Financial reissued a “buy” rating and issued a $120.00 target price on shares of Viking Therapeutics in a research note on Monday, June 17th. Raymond James upped their price objective on Viking Therapeutics from $116.00 to $118.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 25th. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Viking Therapeutics in a research report on Thursday, July 25th. Finally, Morgan Stanley started coverage on shares of Viking Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating and a $105.00 price target on the stock.
Get Our Latest Analysis on Viking Therapeutics
Insider Transactions at Viking Therapeutics
Institutional Trading of Viking Therapeutics
Hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC bought a new stake in Viking Therapeutics during the first quarter valued at about $294,380,000. Vanguard Group Inc. lifted its position in shares of Viking Therapeutics by 44.7% in the first quarter. Vanguard Group Inc. now owns 7,785,724 shares of the biotechnology company’s stock worth $638,429,000 after buying an additional 2,403,820 shares in the last quarter. Perpetual Ltd bought a new position in Viking Therapeutics during the first quarter valued at approximately $78,586,000. Hood River Capital Management LLC bought a new stake in Viking Therapeutics in the 1st quarter worth approximately $55,098,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Viking Therapeutics during the 4th quarter worth approximately $12,341,000. Institutional investors own 76.03% of the company’s stock.
Viking Therapeutics Stock Down 8.9 %
Shares of NASDAQ VKTX opened at $58.39 on Wednesday. The company has a market cap of $6.44 billion, a P/E ratio of -62.78 and a beta of 1.03. Viking Therapeutics has a 52 week low of $8.28 and a 52 week high of $99.41. The business has a 50-day simple moving average of $56.85 and a two-hundred day simple moving average of $63.23.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last issued its quarterly earnings data on Wednesday, July 24th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.06. During the same quarter in the previous year, the firm posted ($0.19) EPS. Equities research analysts anticipate that Viking Therapeutics will post -0.99 EPS for the current year.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
- Five stocks we like better than Viking Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Small Cap Stocks That Insiders Are Buying
- How to Read Stock Charts for Beginners
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- The Basics of Support and Resistance
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.